Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis

Journal of Neuroimmunology

Volumn 306, Issue , 2017, Pages 11-18

  Ramakrishnan, V ^a   Akram Husain, R S ^a   Ahmed, Shiek SSJ ^a  

^a CHETTINAD HOSPITAL AND RESEARCH INSTITUTE   (India)

Author keywords

IL 10 gene; Meta analysis; Multiple sclerosis; Promoter; SNP

Indexed keywords

INTERLEUKIN 10; IL10 PROTEIN, HUMAN;

ALLELE; ARTICLE; ASIAN; CASE CONTROL STUDY; CAUCASIAN; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IL 10 GENE; MULTIPLE SCLEROSIS; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; GENETIC ASSOCIATION STUDY; GENETICS; META ANALYSIS; RISK FACTOR;

GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 85013782844     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2017.02.015     Document Type: Article

References (34)

1. Amirzargar, F., Khosravi, S., Dianat, F., Hushmand, P., Maryousef, A., Foroushani, B., Nikbin, Profile of cytokine gene polymorphisms in Iranian multiple sclerosis patients. Mult. Scler. 13 (2007), 253–255.
2. Azarpira, N., Haghighi, A., Pourjafar, M., Shariat, A., Interleukin 10 gene polymorphism in Iranian patients with multiple sclerosis. Acta Neurol. Taiwanica 19 (2010), 107–111.
3. Boxel-Dezaire, A.H., Hoff, S.C., Van Oosten, B.W., Verweij, C.L., Drager, A.M., Ader, H.J., et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45 (1999), 695–703.
4. Brinza, D., Zelikovsky, A., Case (Control)-Free Multi-SNP Combinations in Case-Control Studies. 2006 (Algorithmic Biol).
5. De Jong, B.A., Westendorp, R.G., Eskdale, J., Uitdehaag, B.M., Huizinga, T.W., Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum. Immunol. 63 (2002), 281–285.
6. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986), 177–188.
7. Egger, M., Smith, G.D., Schneider, M., Minder, C., Bias in Meta-Analysis Detected by a Simple. 1997 (Graphical Test).
8. Forte, G.I., Ragonese, P., Salemi, G., Scola, L., Candore, G., et al. Search for genetic factors associated with susceptibility to multiple sclerosis. Ann. N. Y. Acad. Sci. 1067 (2006), 264–269.
9. Gao, L., Li, Z., Chang, S., Wang, J., Association of interleukin-10 polymorphisms with schizophrenia: a meta-analysis. PLoS One, 9, 2014, e90407.
10. Goldenberg, M., Marvin, Multiple sclerosis review. Pharmacy Ther., 37, 2012, 175.
11. Goris, A., Liston, A., The immunogenetic architecture of autoimmune disease. Cold Spring Harb. Perspect. Biol., 4, 2012, a007260.
12. Goris, I., Pauwels Dubois, B., Progress in multiple sclerosis genetics. Curr. Genomics 13 (2012), 646–663.
13. Gorman, R., Lucas, B., Taylor, B., Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int. J. Mol. Sci. 13 (2012), 11718–11752.
14. Hellings, J., Raus, P., Stinissen, S., Insights into the immuno pathogenesis of multiple sclerosis. Immunol. Res. 25 (2002), 27–51.
15. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ (Clin. Res. Ed.) 327 (2003), 557–560.
16. Huang, Y., Yang, Z., Liang, M., Kang, Y., Li, Kuang F., Association between the CD24 Ala57Val polymorphism and risk for multiple sclerosis and systemic lupus erythematosus: a meta-analysis. Sci. Rep., 5, 2015, 9557.
17. Leray, T., Moreau, A., Fromont, G., Edan, S., Epidemiology of multiple sclerosis. Rev. Neurol. 172 (2016), 3–13.
18. Maurer, M., Kruse, N., Giess, R., Toyka, K.V., Rieckmann, P., Genetic variation at position − 1082 of the interleukin 10 (IL-10) promoter and the outcome of multiple sclerosis. J. Neuroimmunol. 104 (2000), 98–100.
19. Mihailova, S., Ivanova, M., Mihaylova, A., Quin, L., Mikova, O., Naumova, E., Pro-and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J. Neuroimmunol. 168 (2005), 138–143.
20. Mirowska-Guzel, D., Gromadzka, G., Mach, A., Czlonkowski, A., Czlonkowska, A., Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J. Neuroimmunol. 236 (2011), 87–92.
21. Moore, K.W., De Waal Malefyt, R., Coffman, R.L., Garra, A.O., Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001), 683–765.
22. Mosser, D.M., Zhang, X., Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226 (2008), 205–218.
23. Myhr, K.M., Vagnes, K.S., Maroy, T.H., Aarseth, J.H., Nyland, H.I., Vedeler, C.A., Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J. Neurol. Sci. 202 (2002), 93–97.
24. O'Doherty, C., Favorov, A., Heggarty, S., Graham, C., Favorova, O., Ochs, M., et al. Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients. Pharmacogenomics 10 (2009), 1177–1186.
25. Oksenberg, J.R., Barcellos, L.F., The complex genetic aetiology of multiple sclerosis. J. Neurovirol. 6 (2000), 10–14.
26. Oksenberg, J.R., Barcellos, L.F., Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 6 (2005), 375–387.
27. Pickard, C., Mann, P.B., Sinnott, M., Boggild, C., Hawkins, R.C.S., Donn, R.P., Interleukin-10 (IL-10) promoter polymorphisms and multiple sclerosis. J. Neuroimmunol. 101 (1999), 207–210.
28. Ramakrishnan, V., Alu Alphonsa, T., Akram Husain, R.S., Shiek Ahmed, S.S.J., Subramaniyan, K., Kumar, Suresh, Association of rs1801582 and rs1801334 PARK2 polymorphisms with risk of Parkinson's disease: a case-control study in South India and meta-analysis. Meta Gene 10 (2016), 32–38.
29. Shiek Ahmed, S.S.J., Akram Husain, R.S., Kumar, S., Ramakrishnan, V., Association between MDR1 gene polymorphisms and Parkinson's disease in Asian and Caucasian populations: a meta-analysis. J. Neurol. Sci. 368 (2016), 255–262.
30. Smith, A.J., Humphries, S.E., Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 20 (2009), 43–59.
31. Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25 (2010), 603–605.
32. Tarabay, M., Elshazli, R., Settin, A., African vs. Caucasian and Asian difference for the association of interleukin-10 promoter polymorphisms with type 2 diabetes mellitus (a meta-analysis study). Meta gene 9 (2016), 10–17.
33. The International Multiple Sclerosis Genetics Consortium, The Welcome Trust Case Control Consortium 2 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476 (2011), 214–219.
34. Weiner, H.L., The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 65 (2009), 239–248.